A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Key facts

Study ID

NCT00769067

Run by

Pfizer

People needed

188

Starts

2008-11-01

Expected to finish

2014-08-01

Last updated by the study team

2015-10-07

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• advanced measurable Non-Small Cell Lung Cancer (NSCLC);
• progressed after 1-2 prior chemotherapy;
• Eastern Cooperative Oncology Group (ECOG) 0-2;
• tissue available for future KRAS/ EGFR testing

You may not qualify if…

• prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;
• active or untreated Central Nervous System (CNS) metastases;

Where it is running

• Agajanian Institute of Oncology and Hematology — Montebello, California, United States
• Bridgeport Hospital — Bridgeport, Connecticut, United States
• Wittingham Cancer Center @ Norwalk Hospital — Norwalk, Connecticut, United States
• Medical Oncology & Hematology, P.C. — Waterbury, Connecticut, United States
• Winship Cancer Institute at Grady Health Systems — Atlanta, Georgia, United States
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
• Winship Cancer Institute at Emory University — Atlanta, Georgia, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
• Augusta Oncology Associates, P.C. — Augusta, Georgia, United States
• Augusta Oncology Associates, PC — Augusta, Georgia, United States
• John B. Amos Cancer Center — Columbus, Georgia, United States
• Georgia Cancer Specialists — Decatur, Georgia, United States
• The Longstreet Cancer Center — Gainesville, Georgia, United States
• Central Georgia Cancer Care, P.C. — Macon, Georgia, United States
• Northwest Georgia Oncology Center — Marietta, Georgia, United States
• Central Georgia Cancer Care, P.C. — Warner Robins, Georgia, United States
• Kootenai Cancer Center at Post Falls — Post Falls, Idaho, United States
• Kootenai Cancer Center — Post Falls, Idaho, United States
• Midwestern Regional Medical Center — Zion, Illinois, United States
• Center for Blood and Cancer Disorders — Bethesda, Maryland, United States
• Associates in Oncology/Hematology, PC — Rockville, Maryland, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
• The West Clinic — Memphis, Tennessee, United States
• Northwest Alabama Cancer Center — Muscle Shoals, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.